An interventional study of radiofrequency ablation and ballon cryoablation in Atrial Fibrillation, sponsored by Vivantes Netzwerk für Gesundheit GmbH. Status unknown at 1 site in Germany. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2020-04-07.
Sponsored by Vivantes Netzwerk für Gesundheit GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Atrial Fibrillation with a site in Germany — 60 open to participants now, 88 under way, 4 of them phase 3. Atrial Fibrillation · Germany.
Among the 417 studies in Atrial Fibrillation with a site in Germany, this one is the 225th largest by planned enrollment of the 284 interventional ones that give a count, is one of 22 that started in 2020, is one of 166 with no phase, and was the 286th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →60 of the 417 studies in Atrial Fibrillation with a site in Germany are open now. Recruiting first, the newest first:
Technical University of Munich · Sites in Germany
Ages 18–99
Marien Hospital Herne · Sites in Germany
Ages 18+
St. Josefs-Hospital Wiesbaden GmbH · Sites in Germany
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Bayer · Sites in Germany, United States, Belgium and 5 more countries
Ages 18–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 44 · Phase 4 51
First in 2000; this study’s year is marked. 22 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 200 across the 284 interventional studies, 515 across the 131 observational. Of the 289 that completed or were terminated, 92 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
214 of 417 have an industry lead sponsor. The 10 most frequent:
Vivantes Netzwerk für Gesundheit GmbH is the lead sponsor of 4 studies on the registry; none are open to participants now.
Vivantes Netzwerk für Gesundheit GmbH has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
28 of the studies in Atrial Fibrillation with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT05557526Evangelical Hospital DüsseldorfOptimizing Quality of Life by Improved Patient Expectation Following Atrial Fibrillation Catheter Ablation | 2026-12 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
Add all 28 to your calendar (.ics) → With an account.
Among the 417 studies in Atrial Fibrillation with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compares the procedural characteristics and effectivity of radiofrequency ablation and cryoablation in patients with atrial fibrillation that are 75 years or older.
Radiofrequency and cryoballon ablation have been shown to be comparable to each other in terms of safety and effectivity in patients with atrial fibrillation. However, elderly patients have been underrepresented in the previous studies. The number of older patients with atrial fibrillation is high and the number of who undergo an ablation procedure for atrial fibrillation increases steadily. This prospective randomized trial compares the effectivity (recurrency of atrial arrhythmias) and periprocedural characteristics of the two established ablation methods in patients who are 75 years or older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.
Procedure: radiofrequency ablation
Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.
Procedure: ballon cryoablation
ablative treatment as allocated to radiofrequency ablation
ablative treatment as allocated to ballon cryoablation
atrial arrhythmia recurrence
Number of Participants with recurrence of any atrial arrhythmia with a duration of 30 sec or longer 12 months after the ablative treatment
Time frame: 1 year
procedural duration
Duration of the whole procedure \[min\] inclusive preparation (from entrance to the EP lab till exit from the EP lab)
Time frame: periprocedural
time to wake-up after propofol withdrawal
Time from withdrawal of propofole till patient awake and fully oriented (time, place, person)
Time frame: periprocedural
contrast medium dosis
Amount of contrast medium used
Time frame: periprocedural
Propofoldosis
Propofoldosis needed for sedation
Time frame: periprocedural
groin complications
Number of Participants in each randomisation arm with groin complications (hematoma, av fistel, Aneuryma spurium, infection).
Time frame: up to 3 months after dismission from the hospital
Neurological complications
Number of Participants in each randomisation arm with transient ischemic attack, cerebral insult, cerebral haemorrhage
Time frame: 1 year
vascular complications
Number of Participants in each randomisation arm with deep vein thrombosis, peripheral embolism.
Time frame: 1 year
duration of hospital staying [days]
duration of hospital staying: from admission till discharge in days
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2020 (actual). Primary completion is estimated for Jan 2022, 22 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 22 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vivantes Netzwerk für Gesundheit GmbH